Co-crystal structure and inhibition of factor Xa by PD0313052 identifies structurally stabilized active site residues of factor Xa and prothrombinase.

The enzyme complex prothrombinase plays a pivotal role in fibrin clot development through the production of thrombin, making this enzyme complex an attractive target for therapeutic regulation. This study both functionally and structurally characterizes a potent, highly selective, active site directed inhibitor of human factor Xa and prothrombinase, PD0313052, and identifies structurally conserved residues in factor Xa and prothrombinase. Analyses of the association and dissociation of PD0313052 with human factor Xa identified a reversible, slow-onset mechanism of inhibition and a simple, single-step bimolecular association between factor Xa and PD0313052. This interaction was governed by association (k o n ) and dissociation (k o f f ) rate constants of (1.0 ′ 0.1) x 10 7 M - 1 s - 1 and (1.9 ′ 0.5) x 10 - 3 s - 1 , respectively. The inhibition of human factor Xa by PD0313052 displayed significant tight-binding character described by a K i *= 0.29 ′ 0.08 nM. Similar analyses of the inhibition of human prothrombinase by PD0313052 also identified a slow-onset mechanism with a K i * = 0.17 ′ 0.03 nM and a k o n and k o f f of (0.7 ′0.1) x 10 7 M - 1 s - 1 and (1.7 ′ 0.8) x 10 - 3 s - 1 , respectively. Crystals of factor Xa and PD0313052 demonstrated hydrogen bonding contacts within the S1-S4 pocket at residues Serl95, Aspl89, Gly219, and Gly216, as well as interactions with aromatic residues within the S4 pocket. Overall, these data demonstrate that the inhibition of human factor Xa by PD0313052 occurs via a slow, tight-binding mechanism and indicate that active site residues of human factor Xa, including the catalytic Serl95, are effectively unaltered following assembly into prothrombinase.